Since joining CHUM in 2009, Dr. Moishe Liberman, a research member at the Montreal Cancer Institute, has developed internationally recognized expertise in non-invasive thoracic surgery.
Currently, he heads the Tracheobronchial and Esophageal Evaluation Center at CHUM (CETOC), which he established in 2009. This endoscopy center, unique in America, employs minimally invasive techniques for the diagnosis, stratification, and treatment of diseases involving the trachea, bronchi, lungs, esophagus, or stomach.
As a prolific researcher, Dr. Liberman has been involved in over 60 clinical trials throughout his career and has contributed to nearly 170 publications in renowned journals, as well as around fifty book chapters.
Looking towards the future, his innovation and technological development laboratory has a suite of 3D printers and scanners. These tools are used to design prototypes of minimally invasive and endoscopic devices for future cancer treatments through natural orifices, eliminating the need for painful surgeries.
In 2019, within the context of lung cancer treatment, he introduced the widespread use of thoracoscopic lobectomy. This video-assisted thoracic surgical technique, combined with ultrasound sealing of the pulmonary artery, enables a faster recovery for operated patients.
In March 2023, Dr. Liberman and his team successfully performed the first endobronchial lung cancer removal without a scalpel, using a robot designed in Quebec. This North American first was followed in December 2023 by the world’s first successful robotic esophagectomy, utilizing the OTC (outside the cage) approach developed two years earlier for lung surgery at CHUM.
For all these reasons, the members of the scientific council at CRCHUM have decided to award him the 2023 Career Excellence Award, recognizing his exceptional scientific contribution throughout his career.
Other news
